Achieve Life Sciences Inc. (ACHV) falls -1.1950% for June 17

Equities Staff  |

Achieve Life Sciences Inc. (NASDAQ: ACHV) shares fell -1.1950% to end trading Thursday at $8.27 per share - a net change of $-0.1. Shares traded between $8.58 and $8.24 throughout the day.

About Achieve Life Sciences Inc.

Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide. and nearly half a million deaths in the U.S. annually.12 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke. Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

Visit Achieve Life Sciences Inc.’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Achieve Life Sciences Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: Achieve Life Sciences Inc.’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content